NOVABAY PHARMACEUTICALS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0788 USD | +2.34% |
|
-4.37% | -61.37% |
| Mar. 26 | Transcript : NovaBay Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 26, 2024 | |
| Mar. 26 | NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 17.86 | 29.12 | 16.93 | 3.969 | 1.332 | 2.842 | - |
| Enterprise Value (EV) 1 | 17.86 | 29.12 | 16.93 | 3.969 | 1.332 | 2.842 | 2.842 |
| P/E ratio | -1.33 x | -2.25 x | -2.51 x | -0.19 x | -0.05 x | -0.29 x | 3.15 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 2.71 x | 2.93 x | 2.01 x | 0.28 x | 0.09 x | 0.19 x | 0.15 x |
| EV / Revenue | 2.71 x | 2.93 x | 2.01 x | 0.28 x | 0.09 x | 0.19 x | 0.15 x |
| EV / EBITDA | -1.91 x | -4.57 x | -1.94 x | -0.55 x | -0.18 x | -1.09 x | 3.16 x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Price to Book | 18.4 x | 2.36 x | 1.77 x | 0.38 x | 0.26 x | 2.63 x | 7.88 x |
| Nbr of stocks (in thousands) | 797 | 1,194 | 1,284 | 2,035 | 6,529 | 36,061 | - |
| Reference price 2 | 22.40 | 24.40 | 13.18 | 1.950 | 0.2040 | 0.0788 | 0.0788 |
| Announcement Date | 3/26/20 | 3/25/21 | 3/29/22 | 3/30/23 | 3/26/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 6.599 | 9.934 | 8.421 | 14.4 | 14.73 | 14.8 | 19.28 |
| EBITDA 1 | -9.335 | -6.375 | -8.743 | -7.197 | -7.393 | -2.6 | 0.9 |
| EBIT 1 | -9.4 | -6.426 | -8.862 | -7.68 | -7.596 | -3.345 | 0.235 |
| Operating Margin | -142.45% | -64.69% | -105.24% | -53.32% | -51.58% | -22.6% | 1.22% |
| Earnings before Tax (EBT) 1 | -9.652 | -11.03 | -5.824 | -10.61 | -9.64 | -3.345 | 0.235 |
| Net income 1 | -10.49 | -11.04 | -6.559 | -16.26 | -16.7 | -3.345 | 0.235 |
| Net margin | -158.92% | -111.12% | -77.89% | -112.92% | -113.38% | -22.6% | 1.22% |
| EPS 2 | -16.80 | -10.85 | -5.250 | -10.10 | -3.960 | -0.2700 | 0.0250 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 3/26/20 | 3/25/21 | 3/29/22 | 3/30/23 | 3/26/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.84 | 2.641 | 2.629 | 3.045 | 3.826 | 3.643 | 3.124 | 4.61 | 3.265 | 3.727 | 3.28 | 3.575 | 3.71 | 4.235 | 4.385 |
| EBITDA 1 | -2.277 | -3.108 | -2.352 | -2.032 | -0.338 | -2.566 | -1.683 | -1.304 | -1.065 | -3.341 | -1.1 | -0.9 | -0.5 | -0.2 | 0.1 |
| EBIT 1 | -2.289 | -3.195 | -2.382 | -2.152 | -0.457 | -2.689 | -1.734 | -1.355 | -1.116 | -3.391 | -1.32 | -1.08 | -0.71 | -0.235 | -0.36 |
| Operating Margin | -124.4% | -120.98% | -90.6% | -70.67% | -11.94% | -73.81% | -55.51% | -29.39% | -34.18% | -90.98% | -40.24% | -30.21% | -19.14% | -5.55% | -8.21% |
| Earnings before Tax (EBT) 1 | -2.289 | -0.159 | -0.111 | -2.155 | -0.136 | -8.206 | -1.739 | -2.036 | -1.757 | -4.108 | -1.32 | -1.08 | -0.71 | -0.235 | -0.36 |
| Net income 1 | -2.289 | -0.894 | -0.111 | -2.155 | -5.793 | -8.206 | -1.739 | -4.032 | -1.757 | -9.169 | -1.32 | -1.08 | -0.71 | -0.235 | -0.36 |
| Net margin | -124.4% | -33.85% | -4.22% | -70.77% | -151.41% | -225.25% | -55.67% | -87.46% | -53.81% | -246.02% | -40.24% | -30.21% | -19.14% | -5.55% | -8.21% |
| EPS 2 | -1.750 | -1.050 | - | -1.400 | -3.500 | -4.330 | -0.8500 | -1.270 | -0.3700 | -1.330 | -0.1500 | -0.0900 | -0.0600 | -0.0100 | -0.0250 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/11/21 | 3/29/22 | 5/12/22 | 8/11/22 | 11/14/22 | 3/30/23 | 5/11/23 | 8/10/23 | 11/9/23 | 3/26/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 1.220 | 10.30 | 7.450 | 5.190 | 0.7900 | 0.0300 | 0.0100 |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | 0.02 | 0.03 | 0.05 | 0.11 | 0.02 | 0.03 | 0.03 |
| Capex / Sales | 0.29% | 0.26% | 0.62% | 0.78% | 0.13% | 0.2% | 0.16% |
| Announcement Date | 3/26/20 | 3/25/21 | 3/29/22 | 3/30/23 | 3/26/24 | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.0788
USD
Average target price
2.6
USD
Spread / Average Target
+3,199.49%
EPS Revisions
- Stock Market
- Equities
- NBY Stock
- Financials NovaBay Pharmaceuticals
